Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CARM1 | Q86X55 | 5/20 | 0.49 |
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.49 |
| ▸ | PRMT8 | Q9NR22 | 3/20 | 0.49 |
| ▸ | PRMT1 | Q99873 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | PRMT3 | O60678 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16125893 | 0.87 | MAPK1 (0.60) | ALDH1A1MAPK1TDP1HTTLMNA | |
| SCHEMBL16125822 | 0.85 | ALDH1A1 (0.46) | ALDH1A1MAPK1TDP1HTTLMNA | |
| SCHEMBL16124174 | 0.81 | PRMT6 (0.62) | ALDH1A1MAPK1TDP1HTTLMNA | |
| SCHEMBL16068185 | 0.79 | MOK (0.44) | ALDH1A1MAPK1TDP1HTTMAPT | |
| SCHEMBL16121814 | 0.77 | CARM1 (0.42) | ALDH1A1MAPK1CARM1PRMT6PRMT8 | |
| SCHEMBL16126756 | 0.77 | METAP2 (0.43) | ALDH1A1MAPK1TDP1CARM1PRMT6 | |
| SCHEMBL20393050 | 0.76 | CARM1 (0.54) | ALDH1A1MAPK1TDP1HTTMAPT | |
| SCHEMBL20393124 | 0.76 | MAPT (0.41) | ALDH1A1MAPK1TDP1HTTMAPT | |
| SCHEMBL16125361 | 0.74 | ALDH1A1 (0.47) | ALDH1A1MAPK1TDP1LMNACARM1 | |
| SCHEMBL18583256 | 0.73 | ALDH1A1 (0.47) | ALDH1A1MAPK1TDP1HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776972-B2 | Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof | EPIZYME INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9776972-B2 | Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof | EPIZYME INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9732041-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732041-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20170057926-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170057926-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-03-02 | — | — | US | disclosed |
| US-9346761-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2016-05-24 | — | — | US | disclosed |
| US-9346761-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20160137609-A1 | PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-05-19 | — | — | US | disclosed |
| US-20160137609-A1 | PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-05-19 | — | — | US | disclosed |
| WO-2014178954-A1 | PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-11-06 | — | — | WO | disclosed |
| US-20140323537-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140323537-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323537-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | ALDH1A1 686/4885MAPK1 2329/4885TDP1 317/4885 |
| US-20170057926-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | ALDH1A1 686/4885MAPK1 2329/4885TDP1 317/4885 |
| US-20160137609-A1 | PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | ALDH1A1 895/4885MAPK1 1952/4885TDP1 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.